- Home
- LVLU vs TPST Comparison
LVLU vs TPST Comparison
Compare LVLU & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LVLU | TPST |
|---|---|---|
| Founded | 1996 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.1M | 15.2M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | LVLU | TPST |
|---|---|---|
| Price | $13.20 | $2.55 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 2 |
| Target Price | ★ $15.00 | $12.50 |
| AVG Volume (30 Days) | ★ 1.2M | 73.2K |
| Earning Date | 11-12-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $285,413,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.53 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.98 | $2.71 |
| 52 Week High | $15.90 | $13.13 |
Technical Indicators
Market Signals| Indicator | LVLU | TPST |
|---|---|---|
| Relative Strength Index (RSI) | 92.52 | 25.68 |
| Support Level | $5.31 | $2.80 |
| Resistance Level | $15.90 | $3.03 |
| Average True Range (ATR) | 1.29 | 0.17 |
| MACD | 0.83 | 0.12 |
| Stochastic Oscillator | 73.94 | 5.36 |
Price Performance
Historical ComparisonAbout LVLU Lulu's Fashion Lounge Holdings Inc.
Lulus Fashion Lounge Holdings Inc is a fashion brand serving Millennial and Gen Z women. Its products include Fall Dresses, Winter Dresses, Sweater Dresses, Short Dresses, Casual Dresses, Wedding Dresses, and Denims, among others. The company generates majority of its revenue from customers based in the United States.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.